Analytical Data
-
Gene name
IL-22
- Application
-
Alternative Names
ILTIF; Zcyto18; IL-TIF; IL-D110; TIFa; TIFIL-23; IL-22; Cytokine Zcyto18; IL-10-Related T-Cell-Derived Inducible Factor
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
> 95% as determined by SDS-PAGE.
-
Uniprot
G3V6X6
-
Expression Region
Leu34~Val179
-
Molecular Weight
20kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interleukin-22 (IL-22) is a cytokine primarily produced by various immune cells, including Th17 cells, innate lymphoid cells, and specific T cells. It plays a critical role in the immune response, particularly in mucosal immunity and tissue homeostasis. Research has highlighted IL-22's involvement in the pathogenesis of numerous inflammatory and autoimmune diseases, such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease (IBD). The recombinant form of IL-22 has gained attention as a potential therapeutic agent due to its ability to promote tissue repair and enhance the protective functions of epithelial cells. It acts by signaling through the IL-22 receptor, influencing the expression of genes that regulate cellular proliferation, survival, and antimicrobial responses. Understanding the precise mechanisms through which IL-22 operates can open new avenues for treatment strategies, aiming to modulate immune responses and promote healing in affected tissues. Furthermore, the characterization and production of recombinant IL-22 have facilitated various preclinical and clinical studies to explore its efficacy and safety, contributing to the broader field of cytokine-based therapies. The ongoing research seeks to clarify the dual roles of IL-22 in both protective immunity and pathological inflammation, which is crucial for developing targeted therapies that leverage its therapeutic potential while minimizing adverse effects.
